NCI-sponsored Clinical Trial Research Specialist

NCI 资助的临床试验研究专家

• 批准号: 10720142
• 负责人: Thomas J. George
• 金额: $ 11.53万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10720142
• 关键词: Advisory Committees; Award; Cancer Center; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Network; Colon; Colorectal Cancer; Committee Members; Communication; Community Clinical Oncology Program; Conduct Clinical Trials; Development; Disease; Enrollment; Florida; Future; Goals; Health; Hepatobiliary; Institution; Investigational Therapies; Leadership; Malignant neoplasm of anus; Mentorship; National Clinical Trials Network; Neurosecretory Systems; Oncology; Pancreas; Patient Participation; Patients; Pediatric Oncology Group; Peer Review; Positioning Attribute; Process; Productivity; Rectum; Research; Research Personnel; Scientist; Services; Specialist; Voting; Wages; career; cost; data centers; expectation; experience; faculty support; gastrointestinal; improved; meetings; member; next generation; oncology program; oncology trial; programs; rectal; statistical center; success

ABSTRACT NCI-sponsored clinical trials represent some of the highest priority clinical trials conducted by the UF Health Cancer Center (UFHCC). These trials include participation by patients seen at our center as well as those through our academic research consortium across the entire state of Florida to deliver trial access to where patients are. The UFHCC is committed to the success of NCI-sponsored clinical trials through robust partnerships with the National Clinical Trials Network (NCTN) through the Children's Oncology Group (COG), NRG Oncology as well as the Experimental Therapeutics Clinical Trial Network (ETCTN). This commitment is demonstrated at multiple levels including, but not limited to, prioritizing investigator participation in NCI-sponsored clinical trials, facilitating rapid and efficient activation, financially subsidizing the costs of trial conduct, supporting faculty to attend meetings serving as content experts/committee members, hosting the COG Statistical and Data Center, embedding expectations for participation into salary support, and providing a mechanism to allow regional community oncology practices to access trials. My involvement and effort at each of these institutional levels has resulted in improved productivity, efficiency, and impact. These include my leadership as the inaugural UFHCC Associate Director for Clinical Research (ADCR), Director of the Experimental Therapeutics Group, and Director of the GI Oncology Program. Portfolio priority, oversight and enrollments to the NCI-sponsored clinical trials are a demonstrated institutional priority. Within the NCI-sponsored clinical trial networks, I am also active and provide impact through administrative leadership. I serve as the NRG Oncology Co-Chair of the GI Committee, Chair of the Colorectal Cancer Subcommittee, and member of the Communications Committee. I also serve as the UFHCC institutional PI to the ETCTN and Yale LAO member. I am personally involved in the NCI peer-review process by which concepts are evaluated for scientific merit, impact, and feasibility prior to being approved as trials. These reviews occur in the NCI disease-specific Task Forces, specifically, the Esophagogastric, Hepatobiliary, Pancreatic, Neuroendocrine, Colon, and Rectal-Anal Cancer NCI Task Forces as well as trial final approval as a voting member of the NCI Gastrointestinal Steering Committee. Through these positions and with additional contributions, I have actively and positively influenced the current and future landscape of the NCTN and ETCTN programs, particularly the GI Oncology trial portfolio. My career goals include continued service to the NCI-sponsored clinical trial networks through leadership, new member engagement and trial development/completion while simultaneously increasing my institutional engagement through expanded trial conduct and expanding the next generation of capable and diverse NCI clinical investigators leveraging my leadership, experience, mentorship, and sponsorship.

抽象的 NCI赞助的临床试验代表了UF Health进行的一些最高优先级临床试验 癌症中心（UFHCC）。这些试验包括在我们中心看到的患者的参与以及 通过我们在整个佛罗里达州的学术研究联盟，将试用访问权限 患者是。 UFHCC致力于通过强大的合作伙伴关系成功获得NCI赞助的临床试验 通过儿童肿瘤学组（COG），NRG肿瘤学的国家临床试验网络（NCTN） 以及实验治疗临床试验网络（ETCTN）。这项承诺已在 多个级别，包括但不限于优先考虑研究人员参加NCI赞助的临床试验， 促进快速有效的激活，在财务上补贴审判行为成本，支持教师 参加担任内容专家/委员会成员的会议，主持COG统计和数据中心， 将参与的期望嵌入薪水支持中，并提供一种机制以允许区域 访问试验的社区肿瘤学实践。我在这些机构层面中的每个层面中的参与和努力都有 提高了生产率，效率和影响。这些包括我作为首届UFHCC的领导 临床研究副主任（ADCR），实验治疗小组主任和主任 GI肿瘤学计划。 NCI赞助的临床试验的投资组合优先级，监督和入学率是 证明的机构优先级。在NCI赞助的临床试验网络中，我也活跃并提供 通过行政领导的影响。我担任GI委员会的NRG肿瘤学共同主席 大肠癌小组委员会和通信委员会成员。我也是 UFHCC机构PI送给ETCTN和Yale Lao成员。我个人参与了NCI同行评审 在被批准为科学优点，影响和可行性的过程 试验。这些综述发生在NCI疾病特异的工作组中，特别是食管胃的 肝胆，胰腺，神经内分泌，结肠和直肠癌NCI工作队以及试验最终 作为NCI胃肠道转向委员会的投票成员的批准。通过这些位置以及 其他贡献，我已经积极而积极地影响了NCTN的当前和未来景观 和ETCTN计划，特别是GI肿瘤学试验组合。我的职业目标包括继续服务 通过领导，新会员参与和试验，由NCI赞助的临床试验网络 开发/完成，同时通过扩大试验来增加我的机构参与度 进行和扩大下一代能力和多样化的NCI临床研究人员利用我的 领导，经验，指导和赞助。